Vaccination is one of the greatest medical achievements of modern civilization. Could vaccines in tablet form represent the next phase in the evolution of infectious disease protection?
Founded in 2004 and headquartered in South San Francisco, CA, Vaxart stands at the forefront of the next generation of vaccine technology. Vaxart vaccines are administered using convenient room temperature-stable tablets that can be stored and shipped without-refrigeration, are easy to administer, eliminate risk of needle-stick injury and medical waste associated with injectable vaccines. The lead programs are oral vaccines for seasonal influenza, RSV and norovirus. The company is backed by Care Capital, Finney Capital, Quantum Technology Partners, Life Science Angels, Sand Hill Angels and Bay Partners.